Introduction {#S1}
============

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people worldwide, with a frequency that is rapidly rising as the life expectancy increases and the world population becomes older ([@B19], [@B20]; [@B166]; [@B6]). Importantly, AD is characterized by neuronal loss with a slow and progressive decline in memory, language, and other cognitive skills, leading to the final stage of the disease, which is ultimately fatal (Alzheimer's Association 2016).

Despite decades of intense investigation, how degenerative neurodisorders, such as AD, develop remains unclear. Aggregates (plaques) of the amyloid-β peptide (AβP), as well as neurofibrillary tangles of the hyperphosphorylated protein, tau, are among the most sought-after therapeutic targets for AD ([@B18]; [@B112]). However, many clinical trials investigating the effects of anti-amyloid drugs failed to demonstrate improvement in patients' cognitive performance and in countering the primary adverse events ([@B137]). Hence, there is an increasing interest in identifying new strategies to prevent and/or treat AD. For instance, several modifiable risk factors have been considered so far, such as physical inactivity, mood disorders, hypertension, diabetes mellitus, and obesity ([@B120]). Moreover, many reports are now supporting the role of inflammation as a significant pathological driver of AD development and cognitive decline, with evidence that communication between the brain and peripheral immune systems also exists ([@B58]; [@B24]; [@B2]; [@B112]; [@B177]). In this sense, multiple studies have raised that an infectious hypothesis might underlie the pathogenesis of AD ([@B112]). For instance, several studies have demonstrated the presence of herpesvirus (HSV) within the amyloid plaques and in the brains of AD patients ([@B83]; [@B84]; [@B188]; [@B26]). In line with these data, HSV-1 particles can directly induce the fibrillization of Aβ42 *in vitro* ([@B48]). Moreover, two retrospective cohort studies demonstrated that HSV infection significantly increased the risk of developing all-cause dementia. Of note is that this risk was almost eliminated in patients treated with antiherpetics ([@B30]; [@B179]; [@B112]).

Further to these viral effects on AD development, the research in the field has focused its attention on periodontitis, a chronic oral inflammatory condition, and its potential bidirectional link with AD ([@B96]; [@B92]; [@B29]; [@B118]; [@B112]). Importantly, people with periodontitis have an increased risk of developing AD ([@B29]), and those with AD or dementia have impaired oral health, as a result of cognitive decline, and are more prone to develop chronic oral diseases, such as periodontitis, tooth loss, and mucosal lesions ([@B175]; [@B59]; [@B128]; [@B116]). Mechanistically, periodontal pathogens not only invade the oral cavity but can also percolate through the epithelium of the periodontal pocket. From here, they can enter the bloodstream, where they can induce the release of several endotoxins and exotoxins, thus fueling infection in different compartments, including the brain ([@B124]; [@B172]; [@B23]; [@B41]; [@B109]).

Thus, this review aimed to provide the readers with an update on the most recent findings that support the existence of a relationship between periodontitis and AD, with particular emphasis on the common risk factors, phenotype, and bidirectionality.

Pathophysiology of Alzheimer's Disease: β-Amyloid, Tau, and ApoE {#S2}
================================================================

AD is generally classified into two forms: the inherited and the sporadic one ([@B12]; [@B43]). Although there are differences in terms of the triggering factors and the proportion of the affected population, the underlying neuropathology of both conditions remains similar: with patients progressing from normal to mild cognitive impairment (MCI), followed by increasing dementia severity, eventually leading to the final stage of the disease that is ultimately fatal ([@B42]; [@B168]; [@B148]; [@B36]). At a molecular level, both the sporadic and the inherited forms are characterized by the same diagnostic hallmarks such as AβP plaques and neurofibrillary tangles ([@B18]; [@B112]).

AβP Plaques {#S2.SS1}
-----------

In 1907, Alois Alzheimer, a German neurologist, reported the presence of a not well-identified substance in the cortex associated with a progressive behavioral and cognitive disorder ([@B5]; [@B130]). Almost 80 years later, [@B56] demonstrated that this substance was constituted by a ∼4 kDa peptide called AβP. AβP is a fragment derived from the proteolytic cleavage of the amyloid precursor protein (APP). APP is a transmembrane protein with a large ectodomain, a C-terminal (CT) membrane-bound domain and short intracellular domain (AICD) ([@B132]; [@B152]; [@B65]; [@B184]; [@B91]; [@B182]). Importantly, two main proteolytic pathways have been described for APP: the nonamyloidogenic and the amyloidogenic ([@B8]; [Figure 1](#F1){ref-type="fig"}). In the non-amyloidogenic pathway, α-secretase ADAM10 cleaves APP within the Aβ domain, generating a soluble proteolytic fragment, termed sAPPα, and a membrane-bound CT fragment (CTFα). Importantly, CTFα is subsequently processed by another proteolytic process that involved γ-secretases to generate p3 and the AICD. Conversely, in the amyloidogenic pathway, β-secretase 1, also known as β-site APP cleaving enzyme 1 (BACE1), and presenilin-containing γ-secretase (PS/γ-secretase) multi-subunit complex are involved in the generation of AβP ([@B39]; [@B171]; [@B187]; [@B65]; [@B38]; [@B15]; [@B8]). More in detail, BACE1 cleaves APP, liberating a sAPPβ fragment and a 99-amino acid remaining CTF (CTFβ) ([@B38]; [@B8]; [@B15]). Then, the CTFβ is processed at the ε-site by PS/γ-secretase, thereby releasing the AICD ([@B8]; [@B15]). The AICD, either produced by α- or β-secretase, translocates into the nuclei of neurons. Here, it acts as a regulator of gene expression, including that of the Aβ-degrading neprilysin, or is degraded into the cytosol ([@B14]; [@B64]; [@B123]). Importantly, different Aβ forms are generated by PS/γ-secretase cleavages at the ζ and γ sites that trim the transmembrane domain of CTFβ to liberate several forms of AβPs of variable lengths \[from 38 (Aβ38) to 42 (Aβ42) amino acids\] ([@B38]). In this regard, Aβ40 is the major product generated, along with minor amounts of Aβ38 and Aβ42 ([@B38]). However, besides these Aβ forms, it has been reported that, in this process, tiny amounts of Aβ37 and Aβ43 are also generated ([@B38]).

![Diagram of the non-amyloidogenic and the amyloidogenic proteolytic pathway for the amyloid precursor protein (APP). Non-amyloidogenic pathway: α-secretase cleaves the transmembrane protein APP to release the soluble APP fragment, sAPPα. The APP C-terminal fragment is then processed by γ-secretase to release an intracellular domain (AICD) and the P3 fragment. Amyloidogenic pathway: β-secretase processes APP to generate the soluble fragment, sAPP-β, then cleaved γ-secretase Aβ peptides (AβPs), and the AICD.](fphys-11-00683-g001){#F1}

Importantly, although AβP's function is still debated and uncertain, these products are generated throughout life and appear to be normally stimulated by synaptic activity ([@B133]). Conversely, dysregulation of the trimming process of APP can lead to a substantial increase in the levels of the insoluble Aβ42 isoform. This isoform is more prone to form oligomers, which correlate with synaptic dysfunction ([@B75]), protofibrils, or fibrils. Importantly, Aβ42 oligomers represent the most soluble and potent toxic conformers of AD ([@B69]), and their presence correlates with the severity of the disease ([@B121]). However, as recently suggested by [@B67], Aβ42 oligomers are crucial both in physiological and pathological conditions. Indeed, only when present in excessive concentrations or for a prolonged time do these Aβ isoforms can negatively affect long-term potentiation (LTP) and memory. Conversely, low-dose administration positively affects synaptic plasticity and memory.

Thus, all the described processes, in a multitude, generate amyloid plaques resulting toxic to neurons and participating in synaptic destruction during the early stages of AD ([@B8]). However, it is worth stressing that several studies are now supporting the idea that amyloid plaques are not the major toxic AβP entity, and amyloid plaques are not a direct indicator of AβP-induced brain damage in AD. For instance, the Arctic APP mutation (E693G) ([@B127]) leads to enhanced Aβ protofibril formation and AD dementia. Still, no amyloid is visible on positron emission tomography (PET) imaging through the ^11^C-labeled Pittsburgh Compound B (PiB) ligand ([@B150]). Similarly, the Osaka mutation (E693Δ) in APP causes the aggregation of AβP with little amyloid accumulation on PiB-PET ([@B157]). Similarly, transgenic mice carrying the Osaka mutation do not show, by immunohistochemistry, amyloid deposits ([@B178]). Thus, several therapeutic strategies targeting Aβ have been tested in the last decades, such as secretase inhibitors, AβP aggregation inhibitors, and Aβ immunotherapy ([@B137]). However, almost all of these strategies have been discontinued, either because of side effects or the lack of sizable therapeutic effects. Nevertheless, the failure of past clinical trials targeting Aβ does not mean that Aβ is a wrong target. Indeed, the current common concern is that AD patients must be treated at an earlier stage, i.e., right when the pathological "amyloid" cascade likely begins.

Tau Protein {#S2.SS2}
-----------

The protein tau has been identified and purified in 1970 ([@B185]; [@B32]) as a microtubule-interacting protein that stabilizes the neuronal cytoskeleton. The tau protein structure is composed of four main regions: an acidic N-terminal (NT); a proline-rich region responsible for the binding to microtubules; four repeat domains (R1--4), also called microtubule-binding domains (MBDs) ([@B44]; [@B151]; [@B54]); and a C-terminal (CT) region. Importantly, tau activity can be modulated by a wealth of posttranslational modifications (PTMs), such as acetylation, glycosylation, glycation, methylation, truncation, nitration, ubiquitination, and phosphorylation ([@B4]). However, phosphorylation is the most commonly described and investigated since it is centrally involved in the formation of pathologic aggregates. Indeed, the aggregation of tau has been correlated to a broad spectrum of neurological diseases, including AD, known as "tauopathies" ([@B34]; [@B4]). This PTM is physiologically regulated by the balance between tau kinases and phosphatase activities ([@B119]). Importantly, among 85 phosphorylation sites, about 45 of these are phosphorylated in AD brains ([@B129]). More in detail, the early phosphorylation events, at specific serine residues such as Ser199, Ser202/205, and Ser262, can disrupt the association of tau with microtubules. This event, in turn, can lead to alterations in tau-dependent cellular functions with dysregulated axonal growth and vesicle and organelle transport ([@B54]; [@B106]; [@B34]). Otherwise, phosphorylation at other serine residues, such as Ser396, has been suggested as a prominent subsequent event that correlates with the progression of AD ([@B34]).

Like phosphorylation, tau acetylation may arise from multiple mechanisms, and the dysregulation of this process can chiefly contribute to neurodegeneration. For instance, acetylation appears to prevent the binding of ubiquitin and then tau turnover ([@B122]). This event can prompt a rise in cytosolic tau levels that makes the protein prone to aggregation ([@B34]). Finally, unlike other tau posttranslational modifications, *O*-GlcNAcylation seems to be protective against tau-induced pathology. Indeed, in the AD brain, the levels of *O*-GlcNAcylated tau are reduced when compared to those in healthy subjects ([@B111]). Thus, targeting these posttranslational modifications may offer new avenues to prevent tau aggregation, restoring the normal function of the protein.

Apolipoprotein E {#S2.SS3}
----------------

Apolipoprotein E (ApoE) is a primary cholesterol carrier highly expressed in astrocytes and, to a lesser extent, in the microglia which mediates both the transport and delivery of lipids from a cell type to another ([@B115]). In humans, three different alleles (ε2, ε3, and ε4) give rise to three different isoforms of ApoE, which differ in amino acids in positions 112 and 158: ApoE2 (Cys112 and Cys158), ApoE3 (Cys112 and Arg158), and ApoE4 (Arg112 and Arg158) ([@B115]; [@B110]). Importantly, the single amino acid difference in the ApoE protein influences its ability to bind lipids, receptors, and also Aβ(REFF). Indeed, several studies have demonstrated that ApoE has a crucial role in Aβ aggregation and clearance influencing senile plaque formation and AD development ([@B46]; [@B110]). In this context, several reports, including clinical, epidemiological, and genetic studies, have demonstrated an association between ApoE genotypes and AD. For instance, genome-wide association studies (GWAS) have confirmed that the ε4 allele of ApoE is one of the strongest genetic risk factors for AD (REFF). Indeed, the ε4 allele is significantly enriched in AD patients ([@B35]) and is associated with an increased Aβ plaque load in the brain ([@B149]), a higher brain atrophy ([@B1]), and an earlier onset and accelerated progression of the disease ([@B156]).

Moreover, it has been shown that Aβ deposition and aggregation to form senile plaques are a phenomena predominantly observed in ApoE ε4 allele carriers compared with non-carriers ([@B149]; [@B138]; [@B99]). In addition, ApoE ε4 carriers present lower Aβ42 levels in cerebrospinal fluids (CSFs) and higher PiB-positive imaging ([@B143]; [@B76]).

Neuroinflammation in the Pathogenesis of Alzheimer's Disease {#S3}
============================================================

In addition to the two classic diagnostic hallmarks of AD, Aβ plaques and neurofibrillary tangles, the brain of patients with AD exhibits evidence of a sustained inflammatory response ([@B117]; [@B50], [@B49]). In the acute phase, inflammation in the brain represents an established defense against infections, toxins, and injury. However, a disruption in the equilibrium between the pro- and anti-inflammatory mediators results in a chronic inflammatory condition of the brain which is identified as a neuroinflammation ([@B117]). Importantly, this process is currently attributed to the accumulation of reactive microglia and astrocytes that, in AD, appears to be localized to amyloid deposits ([@B5]; [@B17]; [@B169]; [@B117]). Microglia are the resident phagocytes of the central nervous system that are activated in response to AβP accumulation, change their morphology to ameboid cells, migrate to the plaques, and release inflammatory mediators, starting the phagocytosis of the plaques ([@B95]; [@B45]; [@B186]). However, while in the acute phase, the activation of microglia is neuroprotective; in chronic phase, it exacerbates neuroinflammation with consequent neurodegeneration ([@B164]; [@B77]; [@B195]; [@B97]). Emerging evidences have demonstrated that astrocyte-mediated neuroinflammation is also involved in the pathogenesis of neurodegenerative diseases, including AD ([@B181]; [@B33]). Astrocytes are specialized glial cells involved in the production of neurotrophic factors and in the maintenance of the blood brain--barrier (BBB), which protect the central nervous system (CNS) from harmful molecules and cells (including pathogens) ([@B163]). In response to brain insults, these cells become activated, a process known as reactive astrogliosis, and they release reactive oxygen species (ROS), nitric oxide (NO), and pro-inflammatory molecules, including interleukins (ILs) and tumor necrosis factor (TNF) ([@B135]; [@B125]). Although initially this process is aimed at removing noxious stimuli, prolonged astrocyte activation causes detrimental effects, leading to neuronal dysfunction and cell loss ([@B170]). Reactive astrogliosis is a hallmark of AD and is responsible for the exacerbation of AβP-induced neurotoxicity and increased tau phosphorylation ([@B53]; [@B131]).

The involvement of neuroinflammation in the pathogenesis of AD has been supported by observational and epidemiological studies demonstrating that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) can exert beneficial roles in reducing the risk of AD ([@B3]). Moreover, mutations in the genes encoding for immune receptors, including triggering receptor expressed on myeloid cells 2 (TREM2) and myeloid cell surface antigen CD33, have been associated with an elevated risk of developing AD ([@B63]; [@B60]). TREM2 is a transmembrane immune receptor expressed on the surface microglia, and in AD, it is involved in the clearance of Aβ plaques ([@B16]; [@B86]; [@B103]). For this reason, an alteration in TREM2 function is reported as harmful and correlates with AD development. For instance, Wang and coworkers have demonstrated that TREM2 deficiency resulted in an increased AβP accumulation in the brain with reduced clustering of the microglia around the plaques ([@B183]). Importantly, the most common TREM2 mutation is the arginine 47 histidine (R47H) variant, which appears to be associated with a reduced microglial uptake of Aβ and an increased risk of AD development ([@B66]; [@B89]; [@B176]; [@B73]). In this regard, [@B31] demonstrated that AD mice heterozygous for the TREM2 R47H presented reduced immune cells and enhanced neuritic dystrophy around Aβ plaques. Importantly, other TREM2 variants have also been studied for their association with the risk of AD, including R62H ([@B80]; [@B66]; [@B89]; [@B87]; [@B147]; [@B55]; [@B165]; [@B158]). More in detail, Kleinberger et al. demonstrated, in human macrophages *in vitro*, that the TREM2 R62H variant led to an impairment of the phagocytic functions of TREM2 with a reduced uptake of Aβ-LDL complexes compared to wild-type control cells ([@B98]; [@B189]). Of note is that numerous recent findings suggest a link between tau protein aggregation and TREM2 dysfunction. For instance, in the CSF of AD patients, the levels of soluble TREM2 correlate with the amount of total and phosphorylated tau, but not with those of Aβ42 ([@B136]). Importantly, either soluble TREM2 or the phosphorylated tau levels in the CSF are related to the cognitive decline and clinical progression of AD ([@B37]; [@B22]; [@B7]; [@B47]). Contrary to the protective role of TREM2, CD33 induces a negative response in AD because this receptor inhibits phagocytosis, thus reducing microglial uptake and clearance of Aβ ([@B63]). There is also evidence for the existence of a potential crosstalk between CD33 and TREM2. More in detail, Griciuc and coworkers have demonstrated, in a murine model of AD, that loss of CD33 resulted in a decreased Aβ pathology and improved cognition ([@B62]). However, these effects were significantly abrogated by additional TREM2 knockout ([@B62]). Conversely, TREM2 knockout mice presented increased Aβ pathology and exacerbated neurodegeneration, which was not rescued by additional knockout of CD33. Thus, the authors concluded that TREM2 acts downstream of CD33.

Importantly, an association between TREM2 and ApoE has also been discussed. For instance, [@B85] have demonstrated that human ApoE protein contains a binding site for TREM2 (amino acids 130--149), and this binding is isoform-dependent. In line with this report, [@B9] showed that ApoE can increase the phagocytosis of apoptotic neurons *via* TREM2 binding.

Importantly, ApoE activity has also been associated with microglia function. Indeed, LaDu and colleagues have demonstrated that glial cells cultured from ApoE knockout (KO) mice show an increased production of pro-inflammatory markers in response to treatment with Aβ ([@B102]). In line with these data, in 2003, [@B113] have demonstrated that intravenous administration of lipopolysaccharide (LPS) in animals expressing the ε4 allele resulted in a more significant systemic and brain inflammation compared with their ε3 allele counterparts. Analogously, in a tauopathy murine model, ApoE knockdown markedly reduced the activation of microglia and astrocytes ([@B156]). This evidence supports the role of ApoE in neurodegenerative disorders. In the same vein, in one report, Rodriguez and colleagues demonstrated a direct relationship between ApoE, neuroinflammation, and AD ([@B145]). Indeed, in the cortex of transgenic mice expressing five familial AD mutations (FAD), these authors found that the ApoE genotype can influence both Aβ deposition and Aβ-induced glial activation. Consistent with this notion, NSAIDs have been shown to reduce AD risk only in ε4 allele carriers, further supporting the role of the *ApoE* genotype in AD progression and development ([@B174]).

Finally, in addition to these mechanisms, chronic complement activation has been linked to neuroinflammation and AD ([@B52]; [@B51]). In particular, recent pieces of evidence from GWAS have identified complement component receptor (CR1), which binds complement proteins C3b and C4b, as a risk factor for AD ([@B105]). In line with these data, Brouwers and coworkers found four single-nucleotide polymorphisms (SNPs) in the CR1 locus that were associated with elevated levels of Aβ in the CSF of patients with AD ([@B21]). Furthermore, intragenic duplication of low copy repeats (LCR) within the CR1 gene appears to be associated with an increased risk of late-onset AD ([@B101]).

Oral Dysbiosis, Inflammation, and Periodontitis {#S4}
===============================================

The microbiome plays a crucial role in human physiology influencing nutrition, immunity, organ development, and function ([@B172]). In the last decades, the observation that several chronic diseases of the gastrointestinal tract and mouth are associated with the perturbation of microbiome (dysbiosis) has achieved growing attention from scientists. Thus, several studies have been designed to evaluate the potential association between dysbiosis and systemic diseases, including cardiovascular and neurological disorders ([@B11]; [@B140]). Periodontitis is a chronic inflammatory disease caused by the abnormal growth and aggregation of different microorganisms ([@B94]; [@B139]). In periodontitis, of the about 800 microorganisms identified so far, it appears that the vast majority of germs are Gram-positive (early colonizers), followed by Gram-negative bacteria (late colonizers). The latter are on the tooth surface, where they contribute to form the dental plaque ([@B13]; [@B109]). These species include *Porphyromonas gingivalis*, *Aggregatibacter actinomycetemcomitans*, *Treponema denticola*, *Prevotella intermedia*, *Campylobacter rectus*, *Tannerella forsythia*, *Fusobacterium nucleatum*, *Selenomonas* spp., *Parvimonas micra*, and *Eubacterium timidum* ([@B162]; [@B13]; [@B109]). Interestingly, poor oral hygiene results in the increase of the anaerobic environment in the dental plaque, promoting the proliferation of these pathogens and the release of their toxic factors. Moreover, defects in host immunoregulation enable pathogen proliferation and increase local inflammation ([@B10]). Paradoxically, also neutrophils, i.e., the most efficient phagocytes and primary cellular defense recruited to the periodontal pocket, participate in the pathogenesis of periodontitis ([@B72]). Indeed, these immune cell types release several molecules (antimicrobial peptides, enzymes, and reactive oxygen species) that cannot discriminate between pathogens and host tissue. Moreover, certain agents, such as *P. gingivalis*, may subvert neutrophil function, inhibiting the phagocytosis, thus expanding the inflammatory response ([@B161]). Because of this process, additional mediators and cytokines are produced, and more neutrophils, T cells, and monocytes are recruited to the periodontium, leading to chronic local and systemic inflammation ([@B28]; [@B71]; [@B72]). Importantly, T cells promote the release of several cytokines and inflammatory mediators, including tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-4, IL-10, and transforming growth factor β (TGF-β) ([@B61]). In addition to these inflammatory mediators, in response to pathogen infection, the gingival epithelial cells and fibroblasts release other cytokines and mediators \[i.e., IL-1, IL-8, TNF-α, and prostaglandin E2 (PGE2)\] that, in turn, recruit more macrophages and neutrophils. Moreover, these cells promote the expression of matrix metalloproteinases (MMPs), tissue-derived enzymes that participate in the extracellular matrix remodeling. Altogether, these processes result in the stimulation of osteoclasts with subsequent alveolar bone reabsorption ([@B126]; [@B88]). Periodontitis leads to systemic inflammation due to the direct infiltration of bacteria and their virulence factors into the bloodstream ([@B140]). For this reason, periodontitis has been linked to the onset and progression of disorders systemically, such as cancer, diabetes, and cardiovascular and neurological diseases ([@B72]; [@B109]). Importantly, virulence factors expressed by periodontal pathogens are important pathogenic determinants in the initiation, progression, and severity of the disease, and they are responsible for the local and systemic inflammatory response observed in patients with periodontitis. For instance, *P. gingivalis*, long considered as one of the most important members of the periodontopathic microbiota, presents a specific LPS (LPS-Pg), which is recognized by immune cells *via* Toll-like receptors 2 and 4 (TLR2/4), and toxic proteases called gingipains (gps) and other surface components such as carbohydrates and fimbriae ([@B141], [@B142]; [@B79]; [@B82]; [@B74]; [@B190]; [@B68]). gps are cysteine proteases that comprise lysine-gp (Kgp) and arginine-gp A (RgpA) and B (RgpB) are released and transported to the outer bacterial membrane surfaces ([@B68]). In synergy with other virulence factors ([@B68]; [@B41]) these proteases are crucially involved in *P. gingivalis* survival and pathogenicity, allowing the colonization and invasion of gingival/periodontal tissues as well as other tissues, systemically. Importantly, the initial colonization of cells, including fibroblasts, epithelial cells, and other bacteria, is mostly mediated by the coordination between gps and the fimbrial and non-fimbrial components. Moreover, gps play a critical role in iron and nutrient acquisition (*P. gingivalis* agglutinates erythrocytes and lyses them to release hemoglobin), tissue destruction ([@B68]), and in the inactivation of host defenses escaping phagocytosis from immune cells (i.e., neutrophils) ([@B114]). Analogously, *A. actinomycetemcomitans* produces numerous factors that have been well characterized, including adherence proteins, LPS, and toxins like the cytolethal distending toxin (CDT) and leukotoxin (LtxA) ([@B100]; [@B104]; [@B155]). Of note is that these toxins are involved in immune evasion mechanisms ([@B90]). Finally, *T. forsythia* expresses several proteases that contribute to bacterial virulence in multiple manners. For example, proteases participate in degrading the host periodontal tissue, modifying host cell proteins, thus allowing bacterial colonization. Moreover, all the above-mentioned factors are able to activate host degradative enzymes that process components involved in innate and adaptive immunity, thus blocking the host immune response ([@B153]).

Relationship Between Periodontitis and Alzheimer's Disease {#S5}
==========================================================

Although the brain is considered an immune-isolated environment, several shreds of evidence have indicated that systemic inflammation contributes to neurodegeneration through the microglial activation and release of pro-inflammatory molecules, thus driving AD progression ([@B134]; [@B78]). For instance, Capsoni and colleagues, in 2012, have demonstrated that pathogen-free conditions can delay the onset of neurodegeneration in a murine model of nerve growth factor (NGF) deprivation ([@B25]). Furthermore, LPS, the main component of the membrane of Gram-negative bacteria, can be found in large amounts in the brain of AD patients compared to healthy controls ([@B192]). In this context, several studies have found that LPS co-localized with AβPs (Aβ40/42) in the amyloid plaques and around vessels of the brain of AD patients ([@B193]). And peripheral injection of LPS in mice can activate microglia, inducing the release of pro-inflammatory cytokines, such as interleukins and TNF-α ([@B57]). In line with these data, [@B154] demonstrated that mice infused with LPS presented an increased neuroinflammation associated with the enhanced expression and processing of APP and Aβ40/42 levels inside neurons. Lastly, Lee and colleagues showed that in rTg4510 mice expressing a mutated tau protein (TauP301L) that develop tauopathy between 3 and 5 months of age, LPS infusion increases microglial activation and tangle formations ([@B107]). Thus, these reports indicate that bacteria can induce local inflammatory damage, which, in chronic condition, is a trigger of neuroinflammation, constituting a significant contributor of neurodegeneration and AD. For this reason, periodontal pathogens have been investigated for their involvement in AD development and progression. For instance, Chen and colleagues have demonstrated, in a retrospective study, that periodontitis exposure is associated with an about 1.7-fold increase in the risk of developing AD ([@B29]). Analogously, a recent study analyzing the National Health and Nutrition Examination Survey (NHANES) database demonstrated that subjects with mild to severe periodontitis presented a decreased cognitive function compared with the healthy group ([@B173]). Mechanistically, this association has been demonstrated in a different number of studies. [@B93] have observed that elevated serum levels of TNF-α and serum antibodies to *P. gingivalis*, *A. actinomycetemcomitans*, and *T. forsythia* were present in AD patients compared to the controls. In line with these data, Sparks Stein and coworkers demonstrated that antibody levels to *F. nucleatum* and *P. intermedia*, at baseline, resulted significantly increased compared to the controls and correlated with a declined cognitive function in AD patients ([@B167]). Furthermore, in a preclinical study from Ilievski and coworkers, it has been shown that in wild-type mice, *P. gingivalis* infection resulted in the neurodegeneration and formation of extracellular Aβ42 ([@B81]). Analogously, [@B40] demonstrated that *in vitro* LPS (from *A. actinomycetemcomitans*) increased neuroinflammation *via* the activation of microglia and the subsequent increase in pro-inflammatory cytokines and chemokines coupled to the accumulation of Aβ42. Importantly, LPS from *P. gingivalis* (LPS-PG) binds to glial cells ([@B140]), and in the AD brain, it is co-localized with Aβ plaques ([@B192]; [@B194]). Of note is that a direct connection between oral dysbiosis and AD has been suggested by [@B140], who reported the presence of periodontal pathogen components in AD subjects. Subsequently and in line with these data, [@B41] demonstrated that *P. gingivalis* and their virulence factors, gingipains, were exclusively detected in the brain of AD patients compared to the controls. Moreover, in this study, the authors demonstrated that in mice, this oral pathogen migrates from the mouth to the brain, increasing the production of Aβ42, exerting significant neurotoxic effects. Conversely, these processes were abolished following treatment with gingipain inhibitors. In this context, a phase II/III clinical trial has been designed and initiated in order to test the effects of the gingipain inhibitor COR388 in patients with a diagnosis of mild to moderate AD (NCT03823404).

Importantly, as discussed above, the ApoE genotype appears to be crucially involved in neuroinflammation, and as previously demonstrated, it can also contribute to enhancing *P. gingivalis* brain colonization. For example, in 2015, Poole and coworkers observed the presence of *P. gingivalis* DNA ([@B139]) in the brain of ApoE^null^ mice infected at gingival levels with this Gram-positive pathogen. Interestingly, as demonstrated by Singhrao et al., in these mice, gingival infection with *P. gingivalis* also resulted in the early appearance of age-related granules ([@B160]). These data, in line with the results obtained in another study by Hafezi-Moghadam et al., suggest that the lack of functional ApoE protein and the increased systemic inflammation, observed in periodontitis, induce an impairment of the BBB ([@B70]; [@B159]; [@B144]).

Importantly, a dysfunctional BBB allows periodontal pathogens to access the systemic circulation (bacteremia) and invade the brain ([@B70]; [@B159]; [@B144]) and represents an early feature of AD and cognitive decline ([@B180]; [@B27]). In aggregate, these data strengthen the potential relationship between periodontitis and AD development and progression ([Figure 2](#F2){ref-type="fig"}).

![Scheme of the proposed mechanism linking periodontitis to Alzheimer's disease: (1) Oral dysbiosis of the dental plaque leads to proliferation, tissue invasion, and then dissemination into the bloodstream of oral pathogens. (2) Next, the oral pathogens and their toxic molecules, such as lipopolysaccharide (LPS), bind to microglia *via* Toll-like receptors 2/4 (TLR2/4), inducing the release of cytokines (3) and inflammatory mediators that, in turn, lead to APP processing from neuronal cells. (3--4) Subsequently, the activation of β- and γ-secretase leads to an increased secretion of Aβ peptides (AβPs), in particular Aβ42 monomers and sAPPβ, outside of the cells and AICD intracellularly. (4) AβPs form oligomers, protofibrils, or fibrils and then amyloid plaques that are recognized by TREM2 receptors on the microglia plasma membrane, thus triggering an inflammatory response, which again stimulates AβP production. Dysfunctional neurons present also increased tau phosphorylation (p-tau) with the formation of neurofibrillary tangles (p-tau tangles). All these processes induce neuronal degeneration.](fphys-11-00683-g002){#F2}

Conclusion {#S6}
==========

In summary, periodontitis and AD often coexist. However, the current debate focuses on one main question: *what comes first*? Some studies have demonstrated that people with periodontitis present a major risk of developing AD ([@B29]); however, other reports suggest that those with AD or dementia suffer from inadequate oral health, stemming from cognitive decline, and are, therefore, more likely to develop periodontitis ([@B175]; [@B59]; [@B116]). Thus, further studies are urgently needed to establish the *raison d'être* for the mutual association between periodontitis and AD. Along this line of reasoning, the trial (NCT03823404) discussed above shall give us the proof-of-concept of the beneficial role of oral pathogen blockade in human AD. Yet, while waiting for the publication of the trial outcome, we can ascertain, with no additional hesitation, that a more careful dental treatment effectively improves the quality of life/cognitive impairment of patients with mild AD ([@B146]). Likewise, in decreasing the incidence of dementia in patients treated for dementia or periodontitis ([@B108]; [@B191]). Therefore, oral hygiene care strategies should be included in the routine health care of patients with dementia and cognitive impairment and become a dominant part of adult oral health programs to avoid any extra-neuronal source of inflammation as well as to prevent the onset of neurodegeneration. Thus, these findings highlight the necessity to prevent the progression of periodontitis and encourage healthcare service at the national level.
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